Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISLB 2022 | The importance of biomarker testing to reduce disparities in cancer treatment for minority groups

Luis Raez • 4 Nov 2022
ISLB 2022

Luis Raez, MD, FACP, FCCP, Memorial Cancer Institute and Florida International University, Hollywood, FL, discusses the disparities in outcomes of cancer treatment for minority groups. Dr Raez highlights the important role of molecular profiling using liquid biopsy to optimize treatment for these groups. This interview took place at the International Society of Liquid Biopsy (ISLB) 2022 congress in Miami, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research Support: BMS, Genentech/Roche, Pfizer, Nanthealth, MSD, Merck Serono, Lilly Oncology, Boheringer-Ingelheim, Syndax, Novartis, Heat Biologics, Astra-Zeneca, Exosomes DX, Liquid Genomics, Loxo Oncology

More from Luis Raez

6:57
Updates in lung cancer: neoadjuvant immunotherapy and targeted therapies
Luis Raez • 16 Feb 2024
2:21
Current treatment options for NSCLC without driver mutations
Luis Raez • 10 Feb 2023
2:15
The benefits of determining front-line therapy in NSCLC with liquid biopsies
Luis Raez • 10 Feb 2023
2:23
Therapeutic strategies for EGFR-mutated lung cancer
Luis Raez • 10 Feb 2023
The content of VJOncology is intended for healthcare professionals